PhotoCure ASA - PCI technology enhances effect of anti-cancer drug

07-Dec-2005

PhotoCure ASA is, together with its subsidiary PCI Biotech AS, developing a proprietary technology for site-specific drug delivery called photochemical internalisation (PCI). The PCI technology uses light to activate drug delivery and can be used to enhance the effect of drugs by targeted illumination of specific sites of the body (e.g. in tumours). The technology has a potential to improve the effect both of existing drugs and of emerging treatments such as gene therapy and other therapies based on biotechnological principles.

In a scientific article, published in Clinical Cancer Research, it is now demonstrated that PCI can significantly improve the curative effect of the anti-cancer drug bleomycin in animal models. The article shows that by employing PCI, fully curative effects can be achieved with a dose of bleomycin that in itself is inefficient in inducing tumour cure.

The article demonstrates the potential of the PCI technology to make tumour treatment more efficient and specific, potentially making it possible to reduce the required doses of anti-cancer drugs to a level where side effects may be substantially reduced, while the therapeutic effects are improved.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.